The cytoprotective effect of amifostine in acute radiation dermatitis: A retrospective analysis

European Journal of Dermatology

Volumn 12, Issue 5, 2002, Pages 458-462

  Kouvaris, John ^a   Kouloulias, Vassilis ^a   Kokakis, John ^a   Matsopoulos, George ^a   Myrsini, Balafouta ^a   Vlahos, Lambros ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Amifostine; Cytoprotection; Dermatitis; Radiotherapy; Retrospective study

Indexed keywords

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; AMIFOSTINE; ANTIHISTAMINIC AGENT; CORTICOSTEROID; HYDROCORTISONE SODIUM SUCCINATE; PROSTAGLANDIN E2; TROPISETRON;

ALOPECIA; ARTICLE; ASTHENIA; CANCER RADIOTHERAPY; CELL PROTECTION; CONTROLLED STUDY; DERMATITIS; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; HUMAN; MAJOR CLINICAL STUDY; NAUSEA; PELVIS TUMOR; RADIATION DERMATITIS; RADIATION INJURY; RETROSPECTIVE STUDY; SKIN TOXICITY; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; AMIFOSTINE; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS; PRIMARY PREVENTION; PROBABILITY; RADIATION DOSAGE; RADIATION-PROTECTIVE AGENTS; RADIODERMATITIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 0036750646     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Grigsby PW, Russell A, Bruner RND, Eifel P, Koh W, Spanos W, Stetz J, Stitt JA, Sullivan J. Late injury of cancer therapy on the female reproductive tract. Int J Radiat Oncol Biol Phys 1995; 31: 1281-99.
2. Kaanders J, Ang K. Early reactions and dose-limited factors in radiotherapy. Semin Radiat Oncol 1994; 4: 55-67.
3. Archambeau JO, Pezner R, Wasserman T. Pathophysiology of irradiated skin and breast. Int J Radiat Oncol Biol Phys 1995; 31: 1171-85.
4. Roberts WS, Hoffman MS, Kavanagh JJ, Fiorica JV, Greenberg H, Finan MA, Cavanagh D. Further experience with radiation therapy and concomitant intravenous chemotherapy in advanced carcinoma of the lower female genital tract. Gynecol Oncol 1991; 43: 233-6.
5. Archambeau JO. Relative radiation sensitivity of the integumentary system dose response of the epidermal, microvascular, and dermal populations. In: Lett J, Altman K, eds. Advances in radiation biology. San Diego: Academic Press: 1987; 12: 147-203.
6. Archambeau JO, Bennett GW, Abata JJ, Brenneis HJ. Response of swine skin to acute single exposures of x-rays: Quantification of epidermal cell changes. Radiat Res 1979; 79: 298-337.
7. Lee WR, Marcus RB Jr, Sombeck MD, Mendenhall WM, Morgan LS, Freeman DE, Million RR. Radiotherapy alone for carcinoma of the vagina: the importance of overall treatment time. Int J Radiat Oncol Biol Phys 1994; 29: 983-8.
8. Van den Bogaert W, Van der Leest A, Rijnders A, Deluere P, Thames H, Van der Schueren E. Does tumor control decrease by prolonging overall treatment time or interrupting treatment in laryngeal carcinoma? Radiother Oncol 1995; 36: 177-82.
9. Hansen O, Overgaard J, Hansen HS, Hoyer M, Jorgensen KE, Bastholt L, Berthelsen A. Importance of overall treatment time for the outcome of radiotherapy of advanced head and neck carcinoma: dependency of tumor differentiation. Radiother Oncol 1997; 43: 47-51.
10. Capizzi RL. Amifostine: the preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies. Semin Oncol 1996; 23 (suppl. 8): 2-17.
11. McCauley DL. Amifostine: a novel cytoprotective agent. Cancer Pract 1997; 5: 189-91.
12. Valeriote F, Tolen S. Protection and potentiation of nitrogen mustard cytotoxicity by WR-2721. Cancer Res 1982; 42: 4330-1.
13. van der Vijgh WJF, Korst AEC. Amifostine (Ethyol®): pharmacokinetic and pharmacodynamic effects in vivo. Eur J Cancer 1996; 32A: S26-30.
14. Shaw LM, Glover D, Turrisi A, Brown DQ, Bonner HS, Norfleet AL, Weiler C, Glick JH, Kligerman MM. Pharmacokinetics of WR-2721. Pharmacol Ther 1988; 39: 195-201.
15. Calabro-Jones PM, Fahey RC, Smoluk GD, Ward JF. Alkaline phosphatase promotes radioprotection and accumulation of WR-1065 in V79-171 cells incubated in medium containing WR-2721. Int J Radiat Biol 1985; 47: 23-7.
16. Fleckenstein L, Swynnerton NF, Ludden TM, Mangold DJ. Bioavailability and newer methods of delivery of phosphorothioate radioprotectors. Pharmacol Ther 1988; 39: 203-12.
17. Shaw LM, Turrisi AT, Glover DJ, Bonner HS, Norfleet AL, Weiler C, Kligerman MM. Human pharmacokinetics of WR-2721. Int J Radiat Oncol Biol Phys 1986; 12: 1501-4.
18. Korst AEC, Gall HE, Vermorken JB, van der Vijgh WJF. Pharmacokinetics of amifostine and its metabolites in the plasma and ascites of a cancer patient. Cancer Chemother Pharmacol 1996; 9: 162-6.
19. Utley JF, Seaver N, Newton GL, Fahey RC. Pharmacokinetics of WR-1065 in mouse tissue following treatment with WR-2721. Int J Radiat Oncol Biol Phys 1984; 10: 1525-8.
20. Shaw LM, Bonner H, Lieberman R. Pharmacokinetic profile of amifostine. Semin Oncal 1996; 23 (suppl. 8): 18-22.
21. Brizel MD, Wasserman HT, Henke M, Strnad V, Rudat V, Monnier A, Eschwege F, Zhang J, Russell L, Oster W, Sauer R. Phase III Randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 2000; 18: 3339-45.
22. Liu T, Liu Y, He S, Zhang Z, Kligerman MM. Use of radiation with or without WR-2721 in advanced rectal cancer. Cancer 1992; 69: 2820-5.
23. World Health Organization: Handbook for reporting results of cancer treatment. Geneva, Switzertand, World Health Organization, 1979.
24. Trotti A, Byhardt R, Stetz J, Gwede C, Corn B, Fu K, Gunderson L, McCormick B, Morrisintegral M, Rich T, Shipley W, Curran W. Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys 2000; 47: 13-47.
25. Kouvaris JR, Kouloulias VE, Plataniotis GA, Balafouta EJ, Vlahos LJ. Dermatitis during radiation for vulvar carcinoma: prevention and treatment with granulocyte-macrophage colony-stimulating factor impregnated gauze. Wound Repair Regen 2001; 9: 187-93.
26. Bukowski RM. Amifostine (Ethyol): dosing, administration and patient management guidelines. Eur J Cancer 1996; 32A (suppl. 4): S46-9.
27. Ehrhardt JC. Generation of pseudorandom numbers. Med Phys 1986; 13: 240-1.
28. Gleason JM. Statistical tests of the IBM PC pseudorandom number generator. Comput Methods Programs Biomed 1989; 30: 43-6.
29. Fleiss JL. Statistical Methods for Rates and Proportions. John Wiley & Sons, NY; 2nd edition, 1981.
30. Siegel S, Castellan NJ. Nonparametric Statistics for the Behavioral Sciences. McGraw Hill College Div; 2nd edition, 1988.
31. Alberts DS, Speicher LA, Krutzsch M, Wymer J, Capizzi RL, Conlon J, Barrett A, Aickin M. WR-1065, the active metabolite of amifostine (Ethyol®), does not inhibit the cytotoxic effects of a broad range of standard anticancer drugs against human ovarian and breast cancer cells. Eur J Cancer 1996; 32A (suppl. 4): S17-20.
32. Yuhas JM. Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino)-ethylphosphorothioic acid. Cancer Res 1980; 40: 1519-24.
33. Hunter NR, Guttenberger R, Milas L. Modification of radiation-induced carcinogenesis in mice by misonidazole and WR-2721. Int J Radiat Oncol Biol Phys 1992; 22: 795-8.
34. Peters GJ, van der Vijgh WJF. Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (WR-2721): preclinical aspects. Eur J Cancer 1995; 31A (suppl. 1): S1-7.
35. Mohr P, Makki A, Breitbart E, Schadendorf D. Combined treatment of stage IV melanoma patients with amifostine and fotemustine, a pilot study. Melanoma Res 1998; 8: 166-9.
36. Geng L, Hanson WR, Malkinson FD. Topical or systemic 16, 16 dm prostaglandin E2 or WR-2721 (WR-1065) protects mice from alopecia after fractionated irradiation. Int J Radiat Biol 1992; 61: 533-7.
37. Wasserman TH. Radiotherapeutic studies with amifostine (Ethyol). Semin Oncol 1994; 21 (suppl. 11): 21-5.
38. Altmann S, Hoffmanns H. Cytoprotection with amifostine in radiotherapy or radio-chemotherapy of head and neck tumors. Strahlenther Onkol 1999; 175 (suppl. 4): 30-3.
39. Koukourakis MI, Kyrias G, Kakolyris S, Kouroussis C, Frangiadaki C, Giatromanolaki A, Retalis G, Georgoulias V. Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study. J Clin Oncol 2000; 18: 2226-33.
40. Dunst J, Semlin S, Pigorsch S, Muller AC, Reese T. Intermittent use of amifostine during postoperative radiochemotherapy and acute toxicity in rectal cancer patients. Strahlenther Onkol 2000; 176: 416-21.
41. Kouvaris JR, Kouloulias VE, Plataniotis GA, Kokakis JD, Vlahos LJ. Topical granulocyte-macrophage colony-stimulating factor for radiation dermatitis of the vulva. Br J Dermatol 2001; 144: 646-7.
42. Simonen P, Hamilton C, Ferguson S, Ostwald P, O'Brien M, O'Brien P, Back M, Denham J. Do inflammatory processes contribute to radiation induced erythema observed in the skin of humans? Radiother Oncol 1998; 46: 73-82.
43. Schmuth M, Sztankay A, Weinlich G, Linder DM, Wimmer MA, Fritsch PO, Fritsch E. Permeability barrier function of skin exposed to ionizing radiation. Arch Dermatol 2001; 137: 1019-23.
44. Ponten F, Lindman H, Bostrom A, Berne B, Bergh J. Induction of p53 expression in skin by radiotherapy and UV radiation: a randomised study. J Natl Cancer Inst 2001; 93: 128-33.